Baillie Gifford & Co. Acquires 23,807 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Baillie Gifford & Co. raised its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 0.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,705,756 shares of the company’s stock after purchasing an additional 23,807 shares during the period. Baillie Gifford & Co. owned approximately 3.81% of BeiGene worth $831,979,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares during the period. Allspring Global Investments Holdings LLC bought a new position in BeiGene during the third quarter worth $36,000. Headlands Technologies LLC bought a new position in BeiGene during the first quarter worth $50,000. SG Americas Securities LLC bought a new position in BeiGene during the third quarter worth $105,000. Finally, Acadian Asset Management LLC boosted its stake in BeiGene by 204.1% during the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after acquiring an additional 849 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

BeiGene Trading Down 0.2 %

Shares of BeiGene stock opened at $205.04 on Tuesday. The firm has a market cap of $19.96 billion, a PE ratio of -40.36 and a beta of 0.63. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $248.16. The company has a 50 day simple moving average of $212.41 and a two-hundred day simple moving average of $180.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75.

Analyst Ratings Changes

BGNE has been the topic of a number of recent research reports. Citigroup raised their price objective on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Finally, JMP Securities initiated coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $246.21.

Insiders Place Their Bets

In other BeiGene news, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total transaction of $1,053,695.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,070 shares of company stock valued at $4,901,050. 7.43% of the stock is currently owned by corporate insiders.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.